Central venous line thrombosis in children and young adults with thalassemia major.
High doses of intravenous deferoxamine via central venous line (CVL) has recently been shown to improve survival in patients with noncompliant thalassemia major (TM). The aim of this retrospective study was to evaluate the extent of CVL-related thrombosis and to determine the presence of prothrombotic factors in children and young patients with TM on such a regimen. Twenty-three patients (median age 13, range 5-25 years) with TM in whom a tunneled CVL was inserted for intensification of iron chelation were evaluated for signs and symptoms of thrombosis and for inherited and acquired risk factors of thrombosis. Mean duration of CVL placement was 37 +/- 31 months (range 6-98 months). Eight patients (35%) had CVL-related thrombosis diagnosed clinically or by echocardiography. Nine patients (39%) had prothrombotic factors, but the thrombosis subgroup did not differ from the other group in age, platelet counts, duration of CVL placement, or the presence of predisposing prothrombotic factors. Based on the high rate of CVL-related thrombosis, routine monitoring is suggested for CVL thrombosis in this population.
Finkelstein
Yaron
Y
Department of Pediatrics B, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Yaniv
Isaac
I
Berant
Michael
M
Zilber
Rama
R
Garty
Ben-Zion
BZ
Epstein
Orit
O
Lahav
Judith
J
Tamary
Hannah
H
D000293:Adolescent; D000328:Adult; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology*; D017086:beta-Thalassemia / Q000150:complications* / Q000188:drug therapy*
D003676:Deferoxamine